William Kevin Kelly

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Howard I. Scher, Susan Halabi, Ian F. Tannock et al. · Journal of Clinical Oncology · 2008 · 2.2K citations · Full text

Medicine, Oncology, Urology +17

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

William Kevin Kelly, Owen A. O’Connor, Lee M. Krug et al. · Journal of Clinical Oncology · 2005 · 907 citations · Full text

Medicine, Oncology, Pharmacology +16

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

William Kevin Kelly, Susan Halabi, Michael A. Carducci et al. · Journal of Clinical Oncology · 2012 · 483 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

Howard I. Scher, William Kevin Kelly · Journal of Clinical Oncology · 1993 · 413 citations

Medicine, Oncology, Urology +17

Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

Owen A. O’Connor, Mark Heaney, Lawrence B. Schwartz et al. · Journal of Clinical Oncology · 2005 · 403 citations

Medicine, Hematology, Pharmacology +17